SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and OmicronSARS-CoV-2 변종 노출은 Delta 및 Omicron을 포함한 기존 및 신규 균주의 차등 교차 중화를 통해 항체 반응을 이끌어냅니다.Article Published on 2022-06-012022-09-11 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody antibody escape Antibody Response Antibody responses B.1.1.529 B.1.1.529 (omicron) B.1.617.2 B.1.617.2 (Delta) booster vaccination breadth contribute coronavirus COVID-19 cross-neutralization Delta exposure exposure to immune immune exposure immune response immune responses Including increase individual Infection natural infection neutralization Neutralizing antibody response neutralizing antibody responses omicron phenotype Phenotypes respiratory response SARS-CoV-2 sensitivity sera severe acute respiratory syndrome Coronavirus spike mutation Spike protein spike variant strain Transmission vaccination variant variants variants of concern [DOI] 10.1093/infdis/jiab635 PMC 바로가기 [Article Type] Article
Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19COVID-19에 대한 비강내 예방으로서 광범위한 변이 활성을 갖는 계란 유래 항-SARS-CoV-2 면역글로불린 Y(IgY)Clinical Trial Published on 2022-06-012022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 2019 novel coronavirus 2019-nCoV activity Administered Against Alpha anti-SARS-CoV-2 Antiviral approval approvals B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta binding capture chicken immunoglobulin clinical clinical trial clinical trial body Clinical use contagiousness Convalescent patients COVID-19 cross-reactivity Delta demonstrated develop Diseases distribution double-blind effective Emergency use authorization enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Evidence evidence of greater healthy human tissue human tissues IgY Immunity immunized Immunoglobulin immunoglobulin Y index Infectious diseases intranasal intranasally multiple dose multiple doses nasal drop nasal drops nasal mucosa neutralization titer no evidence of Novel coronavirus omicron Phase 1 phase 1 study Placebo placebo-controlled Prevalence Prophylaxis raised Randomized RATs RBD Receptor-binding domain reduce reduced risk Safe safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 viral sensitivity sera Spike protein the receptor-binding domain the SARS-CoV-2 Tolerability Transmission Trial Vaccine Vaccine hesitancy variants variants of concern variety Viral virus [DOI] 10.3389/fimmu.2022.899617 PMC 바로가기 [Article Type] Clinical Trial
ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccinationChAdOx1-S 아데노바이러스 벡터백신을 비강내 투여하여 근육주사에 비해 점막면역력이 우수함Article Published on 2022-06-012022-09-12 Journal: European Journal of Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] adenoviral vector adenoviral vector vaccine Administered Antibody titer applied approved BALB/c mice breakthrough infections CD8 T cell Cellular immune response ChAdOx1-S Complete COVID-19 COVID-19 pandemic elicit elicited exhibiting expressing form full-length humoral IgA IgG antibody Immunity immunization immunized immunized mice induce intramuscular intramuscular vaccination intramuscularly intranasal intranasally lung mice mucosa mucosal mucosal immunity neutralized neutralizing capacity percentage phenotype Prevent Protein robust SARS-CoV-2 sera spike the disease the Spike tissue vaccination Vaccine vaccine vectors. vectors virus entry [DOI] 10.1002/eji.202249823 PMC 바로가기 [Article Type] Article
Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach단백질 스캐폴드에 이식된 수용체 결합 모티프가 있는 SARS-CoV-2 면역원의 설계 및 특성화: 에피토프 중심 백신 접근 방식Article Published on 2022-06-012022-09-12 Journal: International journal of biological macromolecules [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] ACE2 angiotensin Antibody Response antigenic approach caused COVID-19 pandemic effective epitope healthcare immunized immunized mice Immuno-focusing induce Infectious disease interferon γ mice natural infection neutralization neutralizing antibody Non-neutralizing antibodies non-neutralizing epitope predominant Protein RBD RBM Receptor binding domain receptor binding motif robust SARS-CoV-2 SARS-COV-2 infection Scaffold sera Spread T cell T cell response the antibody response the disease the spike protein Vaccine [DOI] 10.1016/j.ijbiomac.2022.04.148 PMC 바로가기 [Article Type] Article
Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine이종 프라임-부스트 COVID-19 백신 투여 6개월 후 오미크론을 포함한 다양한 SARS-CoV-2 변종에 대한 면역 반응Article Published on 2022-05-312022-09-11 Journal: Journal of Travel Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] administration Alpha Analysis B.1 Beta Comparative Comparative analysis Covaxin COVID-19 vaccine Covishield delta variant Delta variants Follow-up groups Heterologous heterologous prime-boost heterologous vaccination Homologous vaccine IgG antibody NAb titer NAb titers neutralization omicron recipient reduction in responses against SARS-CoV-2 sera vaccinees variants variants of SARS-CoV-2 [DOI] 10.1093/jtm/taac033 PMC 바로가기 [Article Type] Article
Vaccination with BNT162b2 and ChAdOx1 nCoV-19 Induces Cross-Reactive Anti-RBD IgG against SARS-CoV-2 Variants including OmicronBNT162b2 및 ChAdOx1 nCoV-19 백신 접종은 Omicron을 포함한 SARS-CoV-2 변이체에 대한 교차 반응성 항-RBD IgG를 유도합니다Article Published on 2022-05-282022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, 치료법, [키워드] adaptive Adaptive immunity age Alpha Alpha variant anti-RBD BNT162b2 booster vaccinations Breakthrough infection breakthrough infections caused ChAdOx1 ChAdOx1 nCoV-19 Cohort contribute Course COVID-19 cross-reactive cross-reactive antibodies cross-reactivity Delta delta variant domain ELISA explain Gamma health-care IgG IgG ELISA IgG level IgG levels Immunity independent independent of individual Infection infection rate lethality magnitude morbidity nucleocapsid nucleocapsid IgG omicron Omicron variants RBD RBD IgG reactivity Receptor-binding domain Receptor-binding domain (RBD) recipient SARS-CoV-2 SARS-CoV-2 testing SARS-CoV-2 variants sera Sex significant increase significantly higher significantly lower Spike protein Spread tested the spike protein university vaccination vaccination rate Vaccine variants variants of concern Vienna VoC VOCs was increased while [DOI] 10.3390/v14061181 PMC 바로가기 [Article Type] Article
Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare ProfessionalsBNT162b2 1차, 2차, 3차 접종 후 SARS-CoV-2 특이 항체 반응의 차이Observational Study Published on 2022-05-272022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료법, [키워드] addition age Analysis Anti-nucleocapsid antibodies anti-nucleocapsid antibody anti-S anti-S antibody anti-S antibody dynamics Anti-spike antibody concentration BMI BNT162b2 BNT162b2 vaccine booster Concentration concentrations COVID-19 Critical determine difference different time point dose doses effective vaccine Effective vaccines first dose hcp healthcare Healthcare professional healthcare professionals humoral immune response humoral immune responses immune responses increase in individual infected individual infected individuals Infection median median value naïve naïve individual naïve individuals of BNT162b2 omicron predictor professional Protective response Safe SARS-CoV-2 second second dose sera Sex significant difference significant differences significantly Spread statistically steadily decreased systemic adverse event systemic adverse events vaccination vaccination schedule Vaccine variant variants of SARS-CoV-2 were used [DOI] 10.3389/fimmu.2022.876533 PMC 바로가기 [Article Type] Observational Study
Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2BA.2 및 BA.3 SARS-CoV-2에 대한 Omicron BA.1의 교차 중화Article Published on 2022-05-262022-09-12 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] COVID-19 vaccine cross-neutralization Frequency geometric mean titer GMT GMTs Heterologous homologous human sera implication initial neutralization neutralize Neutralizing omicron replaced responsible SARS-CoV-2 sera [DOI] 10.1038/s41467-022-30580-5 PMC 바로가기 [Article Type] Article
Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data이종 불활성화 및 아데노바이러스 매개 COVID-19 백신의 면역원성: 실제 데이터Article Published on 2022-05-202022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] adenoviral-vectored vaccine adenoviral-vectored vaccines Anti-RBD IgG AZD1222 B.1.1.7 B.1.351 B.1.617.2 CMIA CoronaVac country COVID-19 COVID-19 vaccine elicited ELISA enrolled enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay followed by group Heterologous heterologous vaccine homologous IgG immunoassay immunogenicity inactivated Limited Microparticle neutralization test Neutralizing activity neutralizing antibody participant recipient recipients regimen response SARS-CoV-2 SARS-CoV-2 variants sera serum sample serum samples subset surrogate virus neutralization test sVNT tested the SARS-CoV-2 Vaccine variant variants variants of concern virus neutralization test was tested Wuhan Wuhan strain [DOI] 10.1016/j.vaccine.2022.04.043 PMC 바로가기 [Article Type] Article
Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants재조합 RBD 백신의 비강내 투여는 오미크론이 포함된 SARS-CoV-2 변이체에 대한 장기 면역을 유도합니다Article Published on 2022-05-172022-09-11 Journal: Signal Transduction and Targeted Therapy [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 administration booster Cell coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 deficiency demonstrated Economy effective vaccine Emergency global health Health IgG antibody immune response immune responses Immunity immunization induce intramuscularly intranasal Local long-lasting lung lymph nodes memory T cell memory T cells mice Migration mucosal mutant strain Neutralizing omicron Omicron variants outbreak persistence proliferation protective immunity RBD required respiratory robust SARS-CoV-2 SARS-CoV-2 variant secretory IgA sera Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Strains Strong suggested systemically T cells T-cell threat Vaccine vaccine candidate Vaccines variant variants waning immunity wild-type [DOI] 10.1038/s41392-022-01002-1 PMC 바로가기 [Article Type] Article